Zhengming Chen, PhD

Associate Professor of Research in Population Health Sciences

Population Health Sciences

Contact & profiles

zhc2006@med.cornell.edu

Appointments

Associate Professor of Research in Population Health SciencesPrimary
Population Health Sciences · 2026–
Assistant Professor
Weill Cornell Graduate School — Population Health Sciences · 2017–

Past Appointments

Assistant Professor of Population Health Sciences
Population Health Sciences · 2020–2026
Assistant Professor of Healthcare Policy and Research
Population Health Sciences · 2019–2020
Instructor in Healthcare Policy and Research
Population Health Sciences · 2016–2018

Centers

Clinical & Translational Science Center
Sandra and Edward Meyer Cancer Centerresearch
Cancer Prevention and Control

Education

M.P.H., Biostatistics
University of South Florida, 2010
Ph.D., Molecular Cancer Biology
Xiamen University (China), 1999
M.S., Microbiology
Xiamen University (China), 1996
B.A., Cell Biology
Xiamen University (China), 1991

Publications

137

Funding

Active

17 grants

Co-I
The role of MGA in the pathogenesis of Richter Transformation
National Cancer Institute · 2026–2031
R37CA304192-01A1
KP
Interrogating and targeting co-inhibitory and co-stimulatory molecules in CAR T-cell Therapies
National Cancer Institute · 2026–2031
R37CA300795-01A1
Co-I
Discovery of a stem cell driving breast cancer spine metastases
National Cancer Institute · 2024–2029
R01CA282815-01A1
Co-I
Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancer
National Cancer Institute · 2023–2028
R37CA279737-01A1
KP
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
National Cancer Institute · 2023–2028· 2 renewals
R01CA282889-01
Co-I
Defining the onset and regulation of myogenic upper urinary tract physiology
National Institute of Diabetes and Digestive and Kidney Diseases · 2024–2028
R01DK133381-03
KP
Abnormal Extracellular Vesicles and Particles from Human Islets Impact T1D progression
National Institute of Diabetes and Digestive and Kidney Diseases · 2023–2028
R01DK137517-04
Co-I
Receptor for hyaluronan-mediated motility isoform B (RHAMM B) in Pancreatic Cancer Metastasis
National Cancer Institute · 2022–2027
R01CA266758-01A1
Co-I
Mechanisms of "fragile" intratumoral regulatory T cells supporting anti-tumor immunity
Cancer Research Institute, Inc. · 2025–2027
CRI13928
KP
Integrative Single Cell Isoform And Chromatin Accessibility Mapping Of Chronic Opioid Exposure In Cognitive Brain Areas In HIV
National Institute on Drug Abuse · 2021–2027
U01DA053625-01
Co-I
Preventing follicular lymphoma progression and transformation through precision therapy
National Cancer Institute · 2022–2027
R01CA270245-01
KP
Characterization of Non-subtype B HIV-1 Reservoirs and its Association with Longitudinal Clinical Outcomes
National Institute of Allergy and Infectious Diseases · 2021–2027
R01AI162221-05
Co-I
Early life respiratory viral infections shape immune development trajectories - Data Management Analysis Core
National Institute of Allergy and Infectious Diseases · 2023–2027 · via St. Jude Children's Research Hospital
U19AI168632-02
Co-I
The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
National Cancer Institute · 2021–2026
U24CA264032-01
Co-I
Novel Complex Structural Variants And Epigenetic Alterations Link The Genomes Of Prostate Cancer In African Americans With Outcome Disparity.
U.S. Department of Defense · 2021–2026
W81XWH-21-1-0762
KP
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
National Cancer Institute · 2023–2026 · via Memorial Sloan Kettering Cancer Center
R01CA274249-01A1
KP
Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
National Cancer Institute · 2019–2025
R01CA242069-01A1

Completed grants (19)

Co-I
Carbon Monoxide-Based Approach for Metastatic Breast Cancer Prevention and Therapy
Manhasset Women's Coalition Against Breast Cancer · 2023–2025
No publications yet
MWCABC 232690-01
Co-I
Mechanism-Based Targeting of Mantle Cell Lymphoma
National Cancer Institute · 2018–2025
P01CA214274-01A1
KP
Tumor-metabolism-driven therapies to overcome TNBC immune resistance
Breast Cancer Alliance Inc. · 2023–2025
BCA 225494-01
KP
Investigating Cellular Immunometabolic Mechanisms Underlying HIV-Related Cardiovascular Disease Risk
National Heart, Lung, and Blood Institute · 2021–2025
R01HL160392-01
KP
A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation
National Institute of Diabetes and Digestive and Kidney Diseases · 2020–2024
R01DK124463-01
KP
Live Imaging Analyses of the Mechanisms Required for Coordinated Urinary Tract Peristalsis in Lower-Order and Higher-Order Mammalian Species
National Institute of Diabetes and Digestive and Kidney Diseases · 2018–2024
R21DK116171-03
KP
Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance
Leukemia & Lymphoma Society · 2018–2023
LLS 180078-01
Co-I
Beyond Apoptosis, Bcl-xL in Tumor Metastasis
National Cancer Institute · 2016–2022
R01CA204916-02
KP
On-Demand Pharmacological Contraception by Blocking ADCY 10
Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2019–2022
P50HD100549-03
KP
Targeting Unmet Clinical Needs for B-Cell Lymphoma
Leukemia & Lymphoma Society · 2016–2021
7012-16 CORE A
Co-I
Defining the Cellular Oncogenome of Kaposi Sarcoma
National Cancer Institute · 2017–2021
R21CA206851-02
KP
Precision medicine deployment of mechanism based Epigenetic – Immune therapy for B-cell lymphoma
Leukemia & Lymphoma Society · 2018–2021
LLS-TRP-6572-19
KP
Targeting oncogenic translation in B-cell lymphomas
Leukemia & Lymphoma Society · 2018–2020
LLS-TRP-R6510-19
KP
Cohesin Regulatory Proteins and Chromosomal Architecture in Normal and Malignant B-Cells
National Cancer Institute · 2018–2019
R01CA228528-01
KP
Targeting oncoprotein expression in follicular lymphoma and mantle cell lymphoma patients with indolent disease: a biomarker-driven proof-of-concept clinical trial
National Cancer Institute · 2017–2018 · via Sloan-Kettering Institute for Cancer Research· 2 renewals
P50CA192937-02
KP
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
National Cancer Institute · 2014–2018
No publications yet
R01CA187109-04
KP
MALT1 Targeted Therapy for B-Cell Lymphoma
National Cancer Institute · 2014–2018
R01CA187492-04
KP
Genetic and Epigenetic Basis of Acute Myeloid Leukemia in Elderly Patients
American Society of Hematology Inc · 2013–2017
ASHI 13040538
KP
Molecular Signatures of Lethal and Indolent Prostate Cancer
National Cancer Institute · 2012–2017
R01CA116337-08

News mentions

1 View all WCM news ↗

American Cancer Society Grant to Fund Research on Urinary Tract Cancer Therapies
April 7, 2026
A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.